Hearing Rehabilitation in Patients With Neurofibromatosis Type 2: The Quebec's Experience With Auditory Implants.
Journal
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
ISSN: 1537-4505
Titre abrégé: Otol Neurotol
Pays: United States
ID NLM: 100961504
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
18
8
2023
pubmed:
8
8
2023
entrez:
8
8
2023
Statut:
ppublish
Résumé
To review a single-center experience with hearing rehabilitation in patients with neurofibromatosis type 2 (NF2) and to describe the auditory outcomes of cochlear implants (CIs) and auditory brainstem implants (ABI) in this population. Retrospective case series. Tertiary referral center. Twelve adult patients with NF2 who received a CI (n = 10) and/or an ABI (n = 5) between 2000 and 2021. Insertion of a CI and/or an ABI in NF2 patients with bilateral vestibular schwannomas (VSs). Patients' demographic data, treatment history, hearing evolution, hearing rehabilitation methods, implant details, and auditory outcomes after implantation. Among those who received a CI, five patients had a stable untreated VS, one patient underwent a cochlear nerve preserving surgery, and four patients received radiotherapy treatments. Six patients became regular users of their device. The median open-set sentence recognition scores were as follows: 0.5% preoperatively, 60% at 1 year postoperatively, and 80% on the most recent audiological evaluation. All patients with an ABI were implanted concomitantly with VS surgical excision, and three of them also received radiotherapy treatments. The median open-set sentence recognition scores were as follows: 4% preoperatively, 26% at 1 year postoperatively, and 0% on the most recent evaluation. Three patients became regular ABI users. Despite major technological advances, auditory outcomes with ABIs remain deceiving. Considering the overall improvement in postoperative auditory performances provided by CIs compared with ABIs, cochlear implantation standouts as a primary mean of hearing rehabilitation in NF2 patients.
Identifiants
pubmed: 37550875
doi: 10.1097/MAO.0000000000003967
pii: 00129492-990000000-00367
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e621-e627Informations de copyright
Copyright © 2023, Otology & Neurotology, Inc.
Déclaration de conflit d'intérêts
The authors disclose no conflicts of interest.
Références
Slattery WH. Neurofibromatosis type 2. Otolaryngol Clin North Am 2015;48:443–60.
Jia H, El Sayed MME, Smail M, et al. Neurofibromatosis type 2: Hearing preservation and rehabilitation. Neurochirurgie 2018;64:348–54.
Maniakas A, Saliba I. Neurofibromatosis type 2 vestibular schwannoma treatment: A review of the literature, trends, and outcomes. Otol Neurotol 2014;35:889–94.
Hosoya M, Wakabayashi T, Wasano K, et al. Understanding the molecular mechanism of vestibular schwannoma for hearing preservation surgery: Otologists' perspective from bedside to bench. Diagnostics (Basel) 2022;12:1044.
Asthagiri AR, Vasquez RA, Butman JA, et al. Mechanisms of hearing loss in neurofibromatosis type 2. PloS One 2012;7:e46132.
Tolisano AM, Baumgart B, Whitson J, Kutz JW Jr. Cochlear implantation in patients with neurofibromatosis type 2. Otol Neurotol 2019;40:e381–5.
Sanna M, Di Lella F, Guida M, Merkus P. Auditory brainstem implants in NF2 patients: Results and review of the literature. Otol Neurotol 2012;33:154–64.
North HJD, Lloyd SKW. Hearing rehabilitation in neurofibromatosis type 2. Adv Otorhinolaryngol 2018;81:93–104.
Ramsden RT, Freeman SR, Lloyd SK, et al. Auditory brainstem implantation in neurofibromatosis type 2: Experience from the Manchester Programme. Otol Neurotol 2016;37:1267–74.
Lloyd SKW, King AT, Rutherford SA, et al. Hearing optimisation in neurofibromatosis type 2: A systematic review. Clin Otolaryngol 2017;42:1329–37.
North HJ, Mawman D, O'Driscoll M, et al. Outcomes of cochlear implantation in patients with neurofibromatosis type 2. Cochlear Implants Int 2016;17:172–7.
Tan H, Jia H, Li Y, et al. Impact of cochlear implantation on the management strategy of patients with neurofibromatosis type 2. Eur Arch Otorhinolaryngol 2018;275:2667–74.
Smith ME, Edmiston R, Trudel M, et al. Cochlear implantation in neurofibromatosis type 2: Experience from the UK neurofibromatosis type 2 service. Otol Neurotol 2022;43:538–46.
Deep NL, Patel EJ, Shapiro WH, et al. Cochlear implant outcomes in neurofibromatosis type 2: implications for management. Otol Neurotol 2021;42:540–8.
Smith MJ, Bowers NL, Bulman M, et al. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology 2017;88:87–92.
Kanzaki J, Tos M, Sanna M, et al. New and modified reporting systems from the consensus meeting on systems for reporting results in vestibular schwannoma. Otol Neurotol 2003;24:642–8; discussion 648-649.
Bergeron F. Développement d'une batterie de tests multimédias visant à évaluer les habiletés audiovisuelles de perception de la parole. Can J Rehab 1998;(11: 182–3).
Tysome JR, Macfarlane R, Durie-Gair J, et al. Surgical management of vestibular schwannomas and hearing rehabilitation in neurofibromatosis type 2. Otol Neurotol 2012;33:466–72.
Slattery W. Neurofibromatosis type 2. In: Brackmann D, Shelton C, Arriaga M eds. Otologic Surgery 4th Edition 2016 . Philadelphia, PA: Elsevier; 2016:619.
Carlson ML, Habermann EB, Wagie AE, et al. The changing landscape of vestibular schwannoma management in the United States—A shift toward conservatism. Otolaryngol Head Neck Surg 2015;153:440–6.
Behr R, Colletti V, Matthies C, et al. New outcomes with auditory brainstem implants in NF2 patients. Otol Neurotol 2014;35:1844–51.
Grayeli AB, Kalamarides M, Bouccara D, Ambert-Dahan E, Sterkers O. Auditory brainstem implant in neurofibromatosis type 2 and non-neurofibromatosis type 2 patients. Otol Neurotol 2008;29:1140–6.
Tadokoro K, Bartindale MR, El-Kouri N, et al. Cochlear implantation in vestibular schwannoma: A systematic literature review. J Neurol Surg B Skull Base 2021;82:643–51.
Savvas E, Heslinga K, Sundermann B, et al. Prognostic factors in cochlear implantation in adults: Determining central process integrity. Am J Otolaryngol 2020;41:102435.
Patel NS, Carlson ML, Link MJ, et al. Cochlear implantation after radiosurgery for vestibular schwannoma. J Neurosurg 2020;135:126–35.
Neff BA, Wiet RM, Lasak JM, et al. Cochlear implantation in the neurofibromatosis type 2 patient: Long-term follow-up. Laryngoscope 2007;117:1069–72.
Arriaga MA, Marks S. Simultaneous cochlear implantation and acoustic neuroma resection: imaging considerations, technique, and functional outcome. Otolaryngol Head Neck Surg 1995;112:325–8.
West N, Sass H, Cayé-Thomasen P. Sporadic and NF2-associated vestibular schwannoma surgery and simultaneous cochlear implantation: A comparative systematic review. Eur Arch Otorhinolaryngol 2020;277:333–42.
Rahne T, Hocke T, Strauß C, et al. Perioperative recording of cochlear implant evoked brain stem responses after removal of the Intralabyrinthine portion of a vestibular schwannoma in a patient with NF2. Otol Neurotol 2019;40:e20–4.
Piccirillo E, Guida M, Flanagan S, et al. CNAP to predict functional cochlear nerve preservation in NF-2: Cochlear implant or auditory brainstem implant. Skull Base 2008;18:281–7.
Kocharyan A, Daher GS, Nassiri AM, et al. Intraoperative use of electrical stapedius reflex testing for cochlear nerve monitoring during simultaneous translabyrinthine resection of vestibular schwannoma and cochlear implantation. Otol Neurotol 2022;43:506–11.
Bestourous DE, Davidson L, Reilly BK. A review of reported adverse events in MRI-safe and MRI-conditional cochlear implants. Otol Neurotol 2022;43:42–7.
Walton J, Donnelly NP, Tam YC, et al. MRI without magnet removal in neurofibromatosis type 2 patients with cochlear and auditory brainstem implants. Otol Neurotol 2014;35:821–5.
Young NM, Hoff SR, Ryan M. Impact of cochlear implant with diametric magnet on imaging access, safety, and clinical care. Laryngoscope 2021;131:E952–6.